ClinicalTrials.Veeva

Menu

PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)

Roche logo

Roche

Status

Completed

Conditions

Diabetes Mellitus Type 2

Treatments

Device: Accu-Chek Aviva Meter

Study type

Interventional

Funder types

Industry

Identifiers

NCT00643474
RD000577
RD0107

Details and patient eligibility

About

This randomized, parallel study compares 2 groups of type 2 non-insulin treated (NIT) diabetes patients using the Accu-Chek Aviva glucometers. One group (Intensive Group) will perform a 4-point daily glucose monitoring profile 3 times a week Monnier-based. These patients will also receive specific glycemic targets and suggestions on how to reach them following lifestyle recommendations. At the same time, investigators will use SMBG results, downloaded from glucometers, to improve patients' therapy. The second group (Control Group), will follow the SMBG standard care usually adopted in their centers. To be eligible, patients do not to have performed a previous intensive SMBG management (the execution of SMBG measurements used to modify lifestyle, diet or physical activity, in a systematic/structured manner and/or to manage therapeutic approach). The anticipated duration of the trial is 12 months, and the target sample size is 1000 individuals.

Enrollment

1,000 patients

Sex

All

Ages

35 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients, 35-75 years of age
  • Non-insulin treated type 2 diabetes for 1-10 years before enrollment
  • Treatment with diet and oral hypoglycemic agents, or with diet only
  • HbAlc of 7.0-9.0%

Exclusion criteria

  • Type 1 diabetes
  • Insulin treatment (for >7 consecutive days)
  • Previous intensive SMBG management (the execution of SMBG measurements used to modify lifestyle, diet or physical activity in a systemic/structured manner and/or to manage therapeutic approach)
  • impending complications of diabetes;
  • serious diseases, including cardiovascular damage or limited life expectancy;
  • pregnancy

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

1,000 participants in 2 patient groups

A
Experimental group
Treatment:
Device: Accu-Chek Aviva Meter
Device: Accu-Chek Aviva Meter
B
Experimental group
Treatment:
Device: Accu-Chek Aviva Meter
Device: Accu-Chek Aviva Meter

Trial contacts and locations

43

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems